These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37745913)

  • 1. A
    Chisari CG; Guadagno J; Adjamian P; Vila Silvan C; Greco T; Bagul M; Patti F
    Ther Adv Neurol Disord; 2023; 16():17562864231195513. PubMed ID: 37745913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials.
    Nicholas J; Lublin F; Klineova S; Berwaerts J; Chinnapongse R; Checketts D; Javaid S; Steinerman JR
    Mult Scler Relat Disord; 2023 Jul; 75():104745. PubMed ID: 37209500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
    Meuth SG; Henze T; Essner U; Trompke C; Vila Silván C
    Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
    [No Abstract]   [Full Text] [Related]  

  • 4. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
    Filippini G; Minozzi S; Borrelli F; Cinquini M; Dwan K
    Cochrane Database Syst Rev; 2022 May; 5(5):CD013444. PubMed ID: 35510826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sativex
    Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
    Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
    Vermersch P
    Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
    Flachenecker P; Henze T; Zettl UK
    Eur Neurol; 2014; 71(5-6):271-9. PubMed ID: 24525548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described 'spasticity-plus syndrome'.
    Patti F; Chisari CG; Fernández Ó; Sarroca J; Ferrer-Picón E; Hernández Vicente F; Vila Silván C
    Eur J Neurol; 2022 Sep; 29(9):2744-2753. PubMed ID: 35590453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Riva N; Mora G; Sorarù G; Lunetta C; Ferraro OE; Falzone Y; Leocani L; Fazio R; Comola M; Comi G;
    Lancet Neurol; 2019 Feb; 18(2):155-164. PubMed ID: 30554828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-interventional, prospective, observational study on spasticity-associated symptom control with nabiximols as add-on therapy in patients with multiple sclerosis spasticity in Austria.
    Guger M; Hatschenberger R; Leutmezer F
    Brain Behav; 2023 Apr; 13(4):e2947. PubMed ID: 36934456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of Available Data for the Efficacy and Effectiveness of Nabiximols Oromucosal Spray (Sativex®) in Multiple Sclerosis Patients with Moderate to Severe Spasticity.
    Conte A; Vila Silván C
    Neurodegener Dis; 2021; 21(3-4):55-62. PubMed ID: 34731865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis.
    Carod-Artal FJ; Adjamian P; Vila Silván C; Bagul M; Gasperini C
    Expert Rev Neurother; 2022 Jun; 22(6):499-511. PubMed ID: 35582858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray).
    Grimaldi AE; De Giglio L; Haggiag S; Bianco A; Cortese A; Crisafulli SG; Monteleone F; Marfia G; Prosperini L; Galgani S; Mirabella M; Centonze D; Pozzilli C; Castelli L
    PLoS One; 2019; 14(7):e0219670. PubMed ID: 31361750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.
    Ferrè L; Nuara A; Pavan G; Radaelli M; Moiola L; Rodegher M; Colombo B; Keller Sarmiento IJ; Martinelli V; Leocani L; Martinelli Boneschi F; Comi G; Esposito F
    Neurol Sci; 2016 Feb; 37(2):235-42. PubMed ID: 26474875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity.
    Paul F; Silván CV
    Neurodegener Dis Manag; 2021 Apr; 11(2):143-153. PubMed ID: 33641348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap.
    Chan A; Silván CV
    Neurodegener Dis Manag; 2022 Jun; 12(3):141-154. PubMed ID: 35377770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nabiximols is Efficient as Add-On Treatment for Patients with Multiple Sclerosis Spasticity Refractory to Standard Treatment: A Systematic Review and Meta-Analysis of Randomised Clinical Trials.
    Kleiner D; Horváth IL; Bunduc S; Gergő D; Lugosi K; Fehérvári P; Hegyi P; Csupor D
    Curr Neuropharmacol; 2023; 21(12):2505-2515. PubMed ID: 37519000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nabiximols and botulinum toxin injections for patients with multiple sclerosis: efficacy on spasticity and spasms in a single-centre experience.
    Sartori A; Dinoto A; Stragapede L; Mazzon G; Morelli ME; Pasquin F; Bratina A; Bosco A; Manganotti P
    Neurol Sci; 2021 Dec; 42(12):5037-5043. PubMed ID: 33742336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Sativex
    Dykukha I; Essner U; Schreiber H; Raithel LM; Penner IK
    Mult Scler Relat Disord; 2022 Dec; 68():104173. PubMed ID: 36174323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice.
    Flachenecker P; Henze T; Zettl UK
    Eur Neurol; 2014; 72(1-2):95-102. PubMed ID: 24943098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.